Essential Premium

How Hiddenite, a Young Long‑Short Fund, Delivered a Second Straight Triple‑Digit Year

Ryan Packard, once an Institutional Investor Rising Star, has delivered a remarkable string of performance with concentrated global equity positions and a disciplined use of options.

The Tiger Grandcub Who Outsmarted the AI Frenzy

While everyone chased Nvidia, Jay Kahn’s fledgling Flight Deck scored a 51.6 percent return by buying the “picks and shovels.”

Sponsored

ETFs: Growing Institutional Adoption

With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma

A slow January IPO market has leaned on biopharma and life‑sciences issuers — several backed by hedge fund specialists — for the few deals getting done.

Related Content

Liquidity Isn’t the Problem You Think It Is, Says Ludovic Phalippou

Michelle Celarier

From Deep Losses to Remarkable Gains: Biopharma’s Wildest Year in Recent Memory

Stephen Taub

Opinion: How Passive Investing Has Pressured IPOs, Stifled Innovation, and Fueled Manias Like Meme Stocks

David Choate

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram